BK
Therapeutic Areas
Aspen Pharmacare Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Anaesthetics Portfolio | Perioperative care | Approved |
| Thrombosis Portfolio (e.g., Arixtra® generics) | Prevention/treatment of blood clots | Approved |
| High Potency & Cytotoxic Steriles | Oncology & supportive care | Approved |
| Biosimilars (e.g., trastuzumab, rituximab) | Oncology, Autoimmune diseases | Approved |
| Infant Nutritionals | Pediatric nutrition | Approved |
| General OTC & Prescription Brands | Various (Pain, Allergy, GI) | Approved |
Leadership Team at Aspen Pharmacare
SS
Stephen Saad
Group Chief Executive
SC
Sean Capazorio
Group Chief Financial Officer
RH
Reginald Haman
Executive Director (Group Enablement)
KD
Kuseni Dlamini
Independent Non-executive Director, Board Chair
LD
Linda de Beer
Independent Non-executive Director
ND
Neo Dongwana
Independent Non-executive Director
TM
Themba Mkhwanazi
Independent Non-executive Director
CM
Chris Mortimer
Independent Non-executive Director
YM
Yvonne Muthien
Independent Non-executive Director
DR
David Redfern
Independent Non-executive Director